Literature DB >> 10779328

Regulation of the Jak2 tyrosine kinase by its pseudokinase domain.

P Saharinen1, K Takaluoma, O Silvennoinen.   

Abstract

Activation of Jak tyrosine kinases through hematopoietic cytokine receptors occurs as a consequence of ligand-induced aggregation of receptor-associated Jaks and their subsequent autophosphorylation. Jak kinases consist of a C-terminal tyrosine kinase domain, a pseudokinase domain of unknown function, and Jak homology (JH) domains 3 to 7, implicated in receptor-Jak interaction. We analyzed the functional roles of the different protein domains in activation of Jak2. Deletion analysis of Jak2 showed that the pseudokinase domain but not JH domains 3 to 7 negatively regulated the catalytic activity of Jak2 as well as Jak2-mediated activation of Stat5. Phosphorylation of Stat5 by wild-type Jak2 was dependent on the SH2 domain of Stat5; however, this requirement was lost upon deletion of the pseudokinase domain of Jak2. Investigation of the mechanisms of the pseudokinase domain-mediated inhibition of Jak2 suggested that this regulation did not involve protein tyrosine phosphatases. Instead, analysis of interactions between the tyrosine kinase domain and Jak2 suggested that the pseudokinase domain interacted with the kinase domain. Furthermore, coexpression of the pseudokinase domain inhibited the activity of the single tyrosine kinase domain. Finally, deletion of the pseudokinase domain of Jak2 deregulated signal transduction through the gamma interferon receptor by significantly increasing ligand-independent activation of Stat transcription factors. These results indicate that the pseudokinase domain negatively regulates the activity of Jak2, probably through an interaction with the kinase domain, and this regulation is required to keep Jak2 inactive in the absence of ligand stimulation. Furthermore, the pseudokinase domain may have a role in regulation of Jak2-substrate interactions.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10779328      PMCID: PMC85631          DOI: 10.1128/MCB.20.10.3387-3395.2000

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  40 in total

1.  The kinase domain of Jak2 mediates induction of bcl-2 and delays cell death in hematopoietic cells.

Authors:  I Sakai; A S Kraft
Journal:  J Biol Chem       Date:  1997-05-09       Impact factor: 5.157

2.  Two novel protein-tyrosine kinases, each with a second phosphotransferase-related catalytic domain, define a new class of protein kinase.

Authors:  A F Wilks; A G Harpur; R R Kurban; S J Ralph; G Zürcher; A Ziemiecki
Journal:  Mol Cell Biol       Date:  1991-04       Impact factor: 4.272

3.  Mutation in the Jak kinase JH2 domain hyperactivates Drosophila and mammalian Jak-Stat pathways.

Authors:  H Luo; P Rose; D Barber; W P Hanratty; S Lee; T M Roberts; A D D'Andrea; C R Dearolf
Journal:  Mol Cell Biol       Date:  1997-03       Impact factor: 4.272

4.  Using CLUSTAL for multiple sequence alignments.

Authors:  D G Higgins; J D Thompson; T J Gibson
Journal:  Methods Enzymol       Date:  1996       Impact factor: 1.600

5.  Crystal structure of the Src family tyrosine kinase Hck.

Authors:  F Sicheri; I Moarefi; J Kuriyan
Journal:  Nature       Date:  1997-02-13       Impact factor: 49.962

6.  The SH2 domains of Stat1 and Stat2 mediate multiple interactions in the transduction of IFN-alpha signals.

Authors:  S Gupta; H Yan; L H Wong; S Ralph; J Krolewski; C Schindler
Journal:  EMBO J       Date:  1996-03-01       Impact factor: 11.598

7.  Distinct tyrosine phosphorylation sites in JAK3 kinase domain positively and negatively regulate its enzymatic activity.

Authors:  Y J Zhou; E P Hanson; Y Q Chen; K Magnuson; M Chen; P G Swann; R L Wange; P S Changelian; J J O'Shea
Journal:  Proc Natl Acad Sci U S A       Date:  1997-12-09       Impact factor: 11.205

8.  Shp-2 tyrosine phosphatase functions as a negative regulator of the interferon-stimulated Jak/STAT pathway.

Authors:  M You; D H Yu; G S Feng
Journal:  Mol Cell Biol       Date:  1999-03       Impact factor: 4.272

Review 9.  Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins.

Authors:  J E Darnell; I M Kerr; G R Stark
Journal:  Science       Date:  1994-06-03       Impact factor: 47.728

10.  JAK2 associates with the erythropoietin receptor and is tyrosine phosphorylated and activated following stimulation with erythropoietin.

Authors:  B A Witthuhn; F W Quelle; O Silvennoinen; T Yi; B Tang; O Miura; J N Ihle
Journal:  Cell       Date:  1993-07-30       Impact factor: 41.582

View more
  102 in total

Review 1.  Jaks and stats as therapeutic targets.

Authors:  J J O'Shea; R Visconti; T P Cheng; M Gadina
Journal:  Ann Rheum Dis       Date:  2000-11       Impact factor: 19.103

2.  Regulation of Jak2 through the ubiquitin-proteasome pathway involves phosphorylation of Jak2 on Y1007 and interaction with SOCS-1.

Authors:  Daniela Ungureanu; Pipsa Saharinen; Ilkka Junttila; Douglas J Hilton; Olli Silvennoinen
Journal:  Mol Cell Biol       Date:  2002-05       Impact factor: 4.272

3.  Autoinhibition of Jak2 tyrosine kinase is dependent on specific regions in its pseudokinase domain.

Authors:  Pipsa Saharinen; Mauno Vihinen; Olli Silvennoinen
Journal:  Mol Biol Cell       Date:  2003-04       Impact factor: 4.138

Review 4.  Chemokine receptors and neural function.

Authors:  Charlene Cho; Richard J Miller
Journal:  J Neurovirol       Date:  2002-12       Impact factor: 2.643

Review 5.  A potential role of ruxolitinib in leukemia.

Authors:  Kiran Naqvi; Srdan Verstovsek; Hagop Kantarjian; Farhad Ravandi
Journal:  Expert Opin Investig Drugs       Date:  2011-06-03       Impact factor: 6.206

6.  Identification of p100 as a coactivator for STAT6 that bridges STAT6 with RNA polymerase II.

Authors:  Jie Yang; Saara Aittomäki; Marko Pesu; Kara Carter; Jussi Saarinen; Nisse Kalkkinen; Elliott Kieff; Olli Silvennoinen
Journal:  EMBO J       Date:  2002-09-16       Impact factor: 11.598

Review 7.  Biology and significance of the JAK/STAT signalling pathways.

Authors:  Hiu Kiu; Sandra E Nicholson
Journal:  Growth Factors       Date:  2012-02-20       Impact factor: 2.511

8.  Modulation of activation-loop phosphorylation by JAK inhibitors is binding mode dependent.

Authors:  Rita Andraos; Zhiyan Qian; Débora Bonenfant; Joëlle Rubert; Eric Vangrevelinghe; Clemens Scheufler; Fanny Marque; Catherine H Régnier; Alain De Pover; Hugues Ryckelynck; Neha Bhagwat; Priya Koppikar; Aviva Goel; Lorenza Wyder; Gisele Tavares; Fabienne Baffert; Carole Pissot-Soldermann; Paul W Manley; Christoph Gaul; Hans Voshol; Ross L Levine; William R Sellers; Francesco Hofmann; Thomas Radimerski
Journal:  Cancer Discov       Date:  2012-05-03       Impact factor: 39.397

9.  Activation of JAK2-V617F by components of heterodimeric cytokine receptors.

Authors:  Anuradha Pradhan; Que T Lambert; Lori N Griner; Gary W Reuther
Journal:  J Biol Chem       Date:  2010-04-02       Impact factor: 5.157

Review 10.  Modulators of erythropoiesis: emerging therapies for hemoglobinopathies and disorders of red cell production.

Authors:  Laura Breda; Stefano Rivella
Journal:  Hematol Oncol Clin North Am       Date:  2014-01-18       Impact factor: 3.722

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.